AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 9 of 14.
Aug 2019
Jul 2019
22 Jul · Analysts
11 Jul · Meeting
5 Jul · Analysts
Jun 2019
13 Jun · Related Party Transactions
May 2019
24 May · Results
16 May · Board meeting
Apr 2019
Mar 2019
Feb 2019
8 Feb · Legal
The exchange asked on 7 Feb 2019
6 Feb · Results
Jan 2019
24 Jan · Board meeting
Dec 2018
14 Dec · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 07-Dec-2018, regarding " AstraZeneca Pharma India Limited has informed the Exchange regarding 'We wish to inform that the Company and Abbott have today entered into a Distribution Agreement for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is Company's leading diabetes medicine. Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET. The Company will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo. '.". On basis of above the Company is required to clarify following: 1. Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc; 2. In case of issuance of shares to the parties, details of issue price, class of shares issued; 3. Whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length; 4. Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship; 5. Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.; 6. Shareholding, if any, in the entity with whom the agreement is executed; 7. Purpose of entering into the agreement; 8. Name(s) of parties with whom the agreement is entered; The response of the Company is awaited.
Nov 2018
13 Nov · Results
Oct 2018
29 Oct · Board meeting
Sep 2018
Aug 2018
13 Aug · Results
3 Aug · Board meeting
Jun 2018
12 Jun · Legal
The exchange asked on 12 Jun 2018
May 2018
22 May · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.21 May · Board meeting
21 May · Results
11 May · Board meeting
Apr 2018
Feb 2018
5 Feb · Results
Jan 2018
Dec 2017
14 Dec · Updates
Nov 2017
6 Nov · Results
Oct 2017
Sep 2017
Aug 2017
8 Aug · Board meeting
8 Aug · Results